Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
entrectinib (Rozlytrek) (1 trial)
pac-1 (2 trials)
procaspase activating compound-1 (1 trial)
Astrocytoma (Phase 1)
Glioblastoma (Phase 1)
Melanoma (Phase 2)
Neoplasms (Phase 1)
Neuroendocrine Tumors (Phase 1)
Uveal Neoplasms (Phase 2)
Trials (3 total)
Trial APIs (3 total)